Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 15NIH 9INDUSTRY 2NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Central Nervous System Neoplasms 7Lymphoma 6Glioblastoma 6Gliosarcoma 5Hodgkin Disease 4Astrocytoma 4Burkitt Lymphoma 3Recurrence 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Glioma 2Waldenstrom Macroglobulinemia 1Plasmablastic Lymphoma 1Neutropenia 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1HIV Infections 1Dendritic Cell Sarcoma, Interdigitating 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiotherapy 18Temozolomide 11Vincristine 10Filgrastim 9Etoposide 9Granulocyte Colony-Stimulating Factor 8Carboplatin 8Cyclophosphamide 7Radiotherapy, Intensity-Modulated 6Cisplatin 6Radiotherapy, Conformal 5Radiosurgery 5Peripheral Blood Stem Cell Transplantation 5Lomustine 5etoposide phosphate 4Thiotepa 3Immunohistochemistry 3Chemotherapy, Adjuvant 3Bevacizumab 3sargramostim 2Topotecan 2Psychiatric Rehabilitation 2Proton Therapy 2Procarbazine 2Microarray Analysis 2Mesna 2Mental Status and Dementia Tests 2Memantine 2In Situ Hybridization, Fluorescence 2Ifosfamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Brain Neoplasms × Carmustine × Clear all
NCT00086879 2017-07-27

Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
110 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡